The US Food and Drug Administration (FDA) has approved the SenSight Directional Lead System used for deep brain stimulation (DBS) from Medtronic plc. According to the Medtronic, SenSight is the first-of-its-kind DBS directional lead that combines the beneﬁts of directionality with the power of sensing, allowing physicians to deliver precise, patient-speciﬁc DBS therapy for the treatment of some symptoms associated with movement disorders like Parkinson's disease, dystonia and essential tremor, and medically refractory epilepsy.
"Until now, sensing capability and directional leads have not been available in the same DBS system, so we have had to choose one technology or the other, based on the predicted needs of each patient," said Kelly D. Foote, MD, professor of neurosurgery at University of Florida. "Now, by coupling this new directional lead with a pulse generator capable of brain sensing, we are excited to be able to oﬀer our patients the synergistic beneﬁts of both technologies. Furthermore, the ability to continuously record brain activity while aﬀected patients go about their daily lives is a powerful research tool that is rapidly improving our understanding of these brain circuitry disorders that diminish the lives of so many people."
DBS is a therapy in which a small pacemaker-like device sends electrical signals through very thin wires, known as "leads," to a targeted area in the brain related to symptoms of certain neurological disorders. A few weeks after surgery, the neurologist will wirelessly adjust the neurostimulator setting to best control symptoms while minimizing potential side eﬀects in a process known as "programming."
For the SenSight directional lead system, Medtronic reimagined how a lead system could be designed, with the patient, neurosurgeon, and programming neurologist in mind. Deliberate choices related to materials and design were made to enhance comfort for patients, allow for more precise stimulation, and streamline the surgical procedure—all while being able to capture objective data for more eﬃcient, informed programming.
SenSight is the ﬁrst directional, sensing-enabled lead designed to enhance the detection of local ﬁeld potentials (LFPs), which are brain signals that correlate with the severity of Parkinson's disease symptoms and are 1 million times smaller than DBS stimulation pulses1. When paired with the Percept PC device, SenSight expands on BrainSense technology, enabling clinicians to capture and record enhanced, directional LFP information from the implanted lead. When physicians can detect LFPs, they can correlate these brain signals with stimulation and events capturing medication, symptoms, or side eﬀects to deliver personalized, data-driven therapy and adjust this therapy as patient needs evolve.
"We are learning from studies across the globe as well as daily patient care that knowing the absolute best location to implant a lead can provide both very eﬃcient and eﬃcacious stimulation," said Leonardo Almeida, MD, assistant professor of neurology at University of Florida. "The more we continue to learn about signals from diﬀerent diseases and where they are located in relation to where we usually target an implant, the more healthcare teams will be able to reﬁne targeting and accurately plan electrode positioning for each speciﬁc patient."
SenSight directional lead systems were ﬁrst implanted at the University of Florida, by multi-disciplinary teams in early June, and a full launch in the US will immediately follow today's announcement. The product also recently received CE Mark and fully launched in Western Europe in March of 2021.
"We are excited to see the clinical beneﬁts that the new SenSight directional lead system will provide to patients and physicians in the US," said Mike Daly, vice president and general manager of Brain Modulation within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. "For over 25 years, Medtronic has driven discoveries and advancements in DBS therapy and we look forward to continuing to deliver meaningful innovation to the movement disorder and epilepsy patient communities."Back To Top
Directional Lead System for DBS Gets FDA Nod. Appl Radiol.